PLCG2 and B-cell chronic lymphocytic leukemia: A viable strategy for relapsed or refractory CLL patients without identified BTK/PLCG2/BCL2 mutations may involve retreatment with either ibrutinib/non-covalent BTKi, venetoclax, or both.